Hepatitis Viruses Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019
Summary
The Publisher's Medical Devices sector report, “Hepatitis Viruses Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019" provides an overview of Hepatitis Viruses Rapid Tests & Point of Care (POC) currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hepatitis Viruses Rapid Tests & Point of Care (POC) pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by the Publisher's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Reasons to Buy
The report enables you to:
Summary
The Publisher's Medical Devices sector report, “Hepatitis Viruses Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019" provides an overview of Hepatitis Viruses Rapid Tests & Point of Care (POC) currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hepatitis Viruses Rapid Tests & Point of Care (POC) pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by the Publisher's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Hepatitis Viruses Rapid Tests & Point of Care (POC) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Hepatitis Viruses Rapid Tests & Point of Care (POC) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to:
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Hepatitis Viruses Rapid Tests & Point of Care (POC) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
1.1 List of Tables1.2 List of Figures
2 Introduction
2.1 Hepatitis Viruses Rapid Tests & Point of Care (POC) Overview
- Hepatitis Viruses Rapid Tests & Point of Care (POC) are the rapid diagnostic tests used to detect the hepatitis viruses or the virus antigens antibodies and generate results immediately in a limited resource setting.
3 Products under Development
3.1 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development
3.2 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Territory
3.3 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path
3.4 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date
3.5 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Ongoing Clinical Trials
4 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products under Development by Companies
4.1 Hepatitis Viruses Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development
4.2 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development
5 Hepatitis Viruses Rapid Tests & Point of Care (POC) Companies and Product Overview
5.1 Abbott Diagnostics Company Overview
5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
5.2 Access Bio Inc Company Overview
5.2.1 Access Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
5.3 Akers Biosciences Inc Company Overview
5.3.1 Akers Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.4 Alere Inc Company Overview
5.4.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview
5.5 Atomo Diagnostics Pty Ltd Company Overview
5.5.1 Atomo Diagnostics Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.6 Biocartis Group NV Company Overview
5.6.1 Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview
5.7 bioLytical Laboratories Inc Company Overview
5.7.1 bioLytical Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview
5.8 Biosurfit, SA Company Overview
5.8.1 Biosurfit, SA Pipeline Products & Ongoing Clinical Trials Overview
5.9 Biotech Consortium India Ltd Company Overview
5.9.1 Biotech Consortium India Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.10 Biotech Resources Pty Ltd Company Overview
5.10.1 Biotech Resources Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.11 Blink AG Company Overview
5.11.1 Blink AG Pipeline Products & Ongoing Clinical Trials Overview
5.12 Cepheid Company Overview
5.12.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview
5.13 Chembio Diagnostic Systems Inc Company Overview
5.13.1 Chembio Diagnostic Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
5.14 ChipCare Corp Company Overview
5.14.1 ChipCare Corp Pipeline Products & Ongoing Clinical Trials Overview
5.15 Co-Diagnostics HBDC, Inc. Company Overview
5.15.1 Co-Diagnostics HBDC, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.16 Co-Diagnostics Inc Company Overview
5.16.1 Co-Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.17 Correlia Biosystems, Inc. Company Overview
5.17.1 Correlia Biosystems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.18 CrossLife Technologies Inc Company Overview
5.18.1 CrossLife Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.19 Daktari Diagnostics, Inc. Company Overview
5.19.1 Daktari Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.20 DCN Diagnostics Company Overview
5.20.1 DCN Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
5.21 Diagnostics For All Inc Company Overview
5.21.1 Diagnostics For All Inc Pipeline Products & Ongoing Clinical Trials Overview
5.22 Diagnostics for the Real World Limited Company Overview
5.22.1 Diagnostics for the Real World Limited Pipeline Products & Ongoing Clinical Trials Overview
5.23 DxDiscovery, Inc. Company Overview
5.23.1 DxDiscovery, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.24 Fast Track Diagnostics Ltd. Company Overview
5.24.1 Fast Track Diagnostics Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.25 genedrive plc Company Overview
5.25.1 genedrive plc Pipeline Products & Ongoing Clinical Trials Overview
5.26 Group K Diagnostics Company Overview
5.26.1 Group K Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
5.27 HLL Lifecare Ltd Company Overview
5.27.1 HLL Lifecare Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.28 ImmunoScience Inc Company Overview
5.28.1 ImmunoScience Inc Pipeline Products & Ongoing Clinical Trials Overview
5.29 MedMira Inc Company Overview
5.29.1 MedMira Inc Pipeline Products & Ongoing Clinical Trials Overview
5.30 Micronics Inc Company Overview
5.30.1 Micronics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.31 Mologic Ltd Company Overview
5.31.1 Mologic Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.32 NanoComposix Inc Company Overview
5.32.1 NanoComposix Inc Pipeline Products & Ongoing Clinical Trials Overview
5.33 NanoRepro AG Company Overview
5.33.1 NanoRepro AG Pipeline Products & Ongoing Clinical Trials Overview
5.34 NOWDiagnostics Inc Company Overview
5.34.1 NOWDiagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.35 Quidel Corp Company Overview
5.35.1 Quidel Corp Pipeline Products & Ongoing Clinical Trials Overview
5.36 Sedia Biosciences Corp Company Overview
5.36.1 Sedia Biosciences Corp Pipeline Products & Ongoing Clinical Trials Overview
5.37 SLS Cell Cure Technologies Pty Ltd Company Overview
5.37.1 SLS Cell Cure Technologies Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.38 University of California Irvine Company Overview
5.38.1 University of California Irvine Pipeline Products & Ongoing Clinical Trials Overview
5.39 Wave 80 Biosciences Inc Company Overview
5.39.1 Wave 80 Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.40 Xagenic Inc Company Overview
5.40.1 Xagenic Inc Pipeline Products & Ongoing Clinical Trials Overview
6 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Recent Developments
6.1 Nov 04, 2019: Quotient reports second quarter fiscal 2020 financial results
6.2 Oct 29, 2019: Merck announces third-quarter 2019 financial results
6.3 Oct 03, 2019: genedrive: Audited final results
6.4 Sep 05, 2019: Biocartis announces H1 2019 results
6.5 Aug 07, 2019: Merck announces leadership changes to investor relations team
6.6 Aug 05, 2019: Quotient Limited Provides Updates on European Hypercare Launch, the CE Mark Submission and U.S. Field Trial for the Initial Serological Disease Screening Microarray, and Reports First Quarter Fiscal 2020 Results
6.7 Jul 30, 2019: Merck announces second-quarter 2019 financial results
6.8 Jul 02, 2019: Quotient Board announces contract extension of CEO Franz Walt
6.9 Jun 20, 2019: Merck hosts 2019 investor day outlining business momentum, strong expected growth and focus on innovative research and development
6.10 Jun 14, 2019: Drug Makers Sue to Block requirement for Listing Prices in TV Ads
7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact Us
7.4 Disclaimer
List of Tables
Table 1: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development
Table 2: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Territory
Table 3: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path
Table 4: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date
Table 5: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Ongoing Clinical Trials
Table 6: Hepatitis Viruses Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development
Table 7: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development
Table 8: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Point-Of-Care Test - Hepatitis C Virus RNA Detection - Product Status
Table 10: Point-Of-Care Test - Hepatitis C Virus RNA Detection - Product Description
Table 11: Access Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: RDT - HCV Infection - Product Status
Table 13: RDT - HCV Infection - Product Description
Table 14: Akers Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 15: PIFA Hep B / Hep C - Product Status
Table 16: PIFA Hep B / Hep C - Product Description
Table 17: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 18: Alere q Analyzer - HCV VL Assay - Product Status
Table 19: Alere q Analyzer - HCV VL Assay - Product Description
Table 20: Atomo Diagnostics Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 21: AtomoRapid - Hepatitis C - Product Status
Table 22: AtomoRapid - Hepatitis C - Product Description
Table 23: Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview
Table 24: Idylla Viral Load Assay - HBV - Product Status
Table 25: Idylla Viral Load Assay - HBV - Product Description
Table 26: Idylla Viral Load Assay - HCV - Product Status
Table 27: Idylla Viral Load Assay - HCV - Product Description
Table 28: bioLytical Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 29: INSTI Test - Hepatitis C - Product Status
Table 30: INSTI Test - Hepatitis C - Product Description
Table 31: Biosurfit, SA Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Spinit Device - Hepatitis C Biomarker Assay - Product Status
Table 33: Spinit Device - Hepatitis C Biomarker Assay - Product Description
Table 34: Biotech Consortium India Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Diagnostic Kit - Hepatitis A - Product Status
Table 36: Diagnostic Kit - Hepatitis A - Product Description
Table 37: Biotech Resources Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 38: ATR-FTIR System - Hepatitis B & C - Product Status
Table 39: ATR-FTIR System - Hepatitis B & C - Product Description
Table 40: Blink AG Pipeline Products & Ongoing Clinical Trials Overview
Table 41: Point-Of-Care Test - Hepatitis C Virus RNA Detection - Product Status
Table 42: Point-Of-Care Test - Hepatitis C Virus RNA Detection - Product Description
Table 43: Cepheid Pipeline Products & Ongoing Clinical Trials Overview
Table 44: GeneXpert Omni - HCV Viral Load - Product Status
Table 45: GeneXpert Omni - HCV Viral Load - Product Description
Table 46: Chembio Diagnostic Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 47: DPP Hepatitis C Virus Assay - Product Status
Table 48: DPP Hepatitis C Virus Assay - Product Description
Table 49: Next Generation DPP HCV Assay - Product Status
Table 50: Next Generation DPP HCV Assay - Product Description
Table 51: Rapid Diagnostic Test - HCV - Product Status
Table 52: Rapid Diagnostic Test - HCV - Product Description
Table 53: ChipCare Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 54: Diagnostic Assay - Hepatitis C - Product Status
Table 55: Diagnostic Assay - Hepatitis C - Product Description
Table 56: Co-Diagnostics HBDC, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 57: Molecular Diagnostic Kit - Hepatitis B - Product Status
Table 58: Molecular Diagnostic Kit - Hepatitis B - Product Description
Table 59: Co-Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 60: Diagnostic Test - Hepatitis C - Product Status
List of Figures
Figure 1: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development
Figure 2: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Territory
Figure 3: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path
Figure 4: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date
Figure 5: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Ongoing Clinical Trials
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Diagnostics
- Access Bio Inc
- Akers Biosciences Inc
- Alere Inc
- Atomo Diagnostics Pty Ltd
- Biocartis Group NV
- bioLytical Laboratories Inc
- Biosurfit, SA
- Biotech Consortium India Ltd
- Biotech Resources Pty Ltd
- Blink AG
- Cepheid
- Chembio Diagnostic Systems Inc
- ChipCare Corp
- Co-Diagnostics HBDC, Inc.
- Co-Diagnostics Inc
- Correlia Biosystems, Inc.
- CrossLife Technologies Inc
- Daktari Diagnostics, Inc.
- DCN Diagnostics
- Diagnostics For All Inc
- Diagnostics for the Real World Limited
- DxDiscovery, Inc.
- Fast Track Diagnostics Ltd.
- genedrive plc
- Group K Diagnostics
- HLL Lifecare Ltd
- ImmunoScience Inc
- MedMira Inc
- Micronics Inc
- Mologic Ltd
- NanoComposix Inc
- NanoRepro AG
- NOWDiagnostics Inc
- Quidel Corp
- Sedia Biosciences Corp
- SLS Cell Cure Technologies Pty Ltd
- University of California Irvine
- Wave 80 Biosciences Inc
- Xagenic Inc
![In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC) - Global Forecast to 2030 - Product Image](http://www.researchandmarkets.com/product_images/12002/12002788_60px_jpg/invitro_diagnostics_market.jpg)
